As vice president of clinical operations for the National Institute of Clinical Research, Dr. Mark Paskewitz draws on more than 12 years of experience in the pharmaceutical field. He previously served as senior director of clinical development for Kyowa Hakko Kirin Pharma, where he led a team that developed the first drug approved to treat the bone disease X-Linked Hypophosphatemia. Dr. Mark Paskewitz oversaw regulatory and administrative processes as well as the details of clinical trials for the drug, which earned its European Medicines Agency and US Food and Drug Administration (FDA) approvals in 2018.

Dr. Mark Paskewitz also served Kyowa Kirin as clinical leader for the Phase 1 trial of a new colorectal cancer drug. Responsible for evaluating the feasibility of pre-clinical initiatives, he also contributed to development on a partnered program with the California company Nuevlo, Inc.

As part of the program’s Joint Steering Committee, Dr. Paskewitz participated in the planning of a drug that would use gastrointestinal growth factor to treat inflammatory bowel disease (IBD) and oral mucositis.